Top

Published in:

01-03-2020 | Epstein-Barr Virus | Review and Perspectives

Thirty years of Epstein-Barr virus-associated gastric carcinoma

Authors: Masashi Fukayama, Hiroyuki Abe, Akiko Kunita, Aya Shinozaki-Ushiku, Keisuke Matsusaka, Tetsuo Ushiku, Atsushi Kaneda

Published in: Virchows Archiv | Issue 3/2020

Abstract

Thirty years have passed since a possible association of Epstein-Barr virus (EBV) with gastric carcinoma was reported. We now know EBV-associated gastric carcinoma to be a specific subtype of gastric carcinoma. Global epigenetic methylation and counteraction of the antitumour microenvironment are two major characteristics of this subtype of gastric carcinoma. Recent development of therapeutic modalities for gastric carcinoma, such as endoscopic mucosal dissection and immune checkpoint inhibitor therapy, has made the presence of EBV infection a biomarker for the treatment of gastric carcinoma. This review presents a portrait of EBV-associated gastric carcinoma from initiation to maturity that we define as the ‘gastritis-infection-cancer sequence’, followed by its molecular abnormalities and interactions with immune checkpoint molecules and the microenvironment. EBV non-coding RNAs (microRNA and circular RNA) and exosomes derived from EBV-infected cells that were previously behind the scenes are now recognized for their roles in EBV-associated gastric carcinoma. The virus utilizes cellular machinery skilfully to control infected cells and their microenvironment. We should thus strive to understand virus-host interactions more fully in the following years to overcome this virus-driven subtype of gastric carcinoma.

Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 15:702–703. https://doi.org/10.1016/s0140-6736(64)91524-7 CrossRef

Young LS, Yap LF, Murray PG (2015) Epstein-Barr virus: more than 50 years old and still providing surprises. Nature Rev Cancer 16:789–802. https://doi.org/10.1038/nrc.2016.92 CrossRef

Burke AP, Yen TS, Shekitka KM, Sobin LH (1990) Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol 3:377–380PubMed

Howe JG, Steitz JA (1986) Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc Natl Acad Sci U S A 83:9006–9010CrossRef

Wu TC, Mann RB, Charache P, Hayward SD, Staal S, Lambe BC, Ambinder RF (1990) Detection of EBV gene expression in reed-Sternberg cells of Hodgkin's disease. Int J Cancer 46:801–804CrossRef

Shibata D, Tokunaga M, Uemura Y, Sato E, Tanaka S, Weiss LM (1991) Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol 139:469–474PubMedPubMedCentral

Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E (1993) Epstein-Barr virus in gastric carcinoma. Am J Pathol 143:1250–1254PubMedPubMedCentral

Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, Takizawa T, Koike M, Mizutani S, Miyaki M, Hirai K (1994) Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Investig 71:73–81PubMed

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterol 137:824–833. https://doi.org/10.1053/j.gastro.2009.05.001 CrossRef

10.

Tsao S, Tsang CM, Lo KW (2017) Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc London B Biol Sci 372:20160270. https://doi.org/10.1098/rstb.2016.0270 CrossRefPubMed

11.

Fukayama M, Kunita A, Kaneda A (2018) Gastritis-infection-cancer sequence of Epstein-Barr virus-associated gastric carcinoma. Adv Exp Med Biol 1045:437–457. https://doi.org/10.1007/978-981-10-7230-7_20 CrossRefPubMed

12.

Niller Niller HH, Banati F, Salamon D (2016) Minarovits J (2016) Epigenetic alterations in Epstein-Barr virus-associated diseases. Adv Exp Med Biol 879:39–69. https://doi.org/10.1007/978-3-319-24738-0_3 CrossRefPubMed

13.

The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202–209. https://doi.org/10.1038/nature13480 CrossRef

14.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24:1449–1458. https://doi.org/10.1038/s41591-018-0101-z CrossRefPubMed

15.

Gao P, Lazare C, Cao C, Meng Y, Wu P, Zhi W, Lin S, Wei J, Huang X, Xi L, Chen G, Hu J, Ma D, Wu P (2019) Immune checkpoint inhibitors in the treatment of virus-associated cancers. J Hematol Oncol 12:58. https://doi.org/10.1186/s13045-019-0743-4 CrossRefPubMedPubMedCentral

16.

Fukayama M, Ushiku T (2011) Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract 207:529–537. https://doi.org/10.1016/j.prp.2011.07.004 CrossRefPubMed

17.

Song HJ, Srivastava A, Lee J, Kim YS, Kim KM, Kang WK, Kim M, Kim S, Park CK, Kim S (2010) Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology 139:84–92.e2. https://doi.org/10.1053/j.gastro.2010.04.002 CrossRefPubMed

18.

Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, Lissowska J, Kim S, Hu N, Gonzalez CA, Yatabe Y, Koriyama C, Hewitt SM, Akiba S, Gulley ML, Taylor PR, Rabkin CS (2014) Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 63:236–243. https://doi.org/10.1136/gutjnl-2013-304531 CrossRefPubMed

19.

Park JH, Kim EK, Kim YH, Kim JH, Bae YS, Lee YC, Cheong JH, Noh SH, Kim H (2016) Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favourable risk factor for lymph node metastasis in submucosa-invasive early gastic cancer. Gastric Cancer 19:1041–1051. https://doi.org/10.1007/s10120-015-0565-1 CrossRefPubMed

20.

Osumi H, Kawachi H, Yoshio T, Ida S, Yamamoto N, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Hiki N, Takeuchi K, Fujisaki J (2019) Epstein-Barr virus status is a promising biomarker for endoscopic resection in early gastric cancer: proposal of a novel therapeutic strategy. J Gastroenterol 54:774–783. https://doi.org/10.1007/s00535-019-01562-0 CrossRefPubMed

21.

Carneiro F, Fukayama M, Grabsch HI, Yasui W (2019) Gastric adenocarcinoma. In WHO Classification Editorial Board. Digestive system tumours (WHO calssification of tumours series, 5^th ed.; vol.1), International Agency for Research on Cancer, Lyon, pp85–95

22.

Watanabe H, Enjoji M, Imai T (1976) Gastric carcinoma with lymphoid stroma. Its morphological characteristics and prognostic correlations. Cancer 38:232–243CrossRef

23.

Gonzalez RS, Cates JMM, Revetta F, McMahon LA, Washington K (2017) Gastric carcinomas with lymphoid stroma: categorization and comparison with solid-type colonic carcinomas. Am J Clin Pathol 148:477–484. https://doi.org/10.1093/ajcp/aqx096 CrossRefPubMedPubMedCentral

24.

Nakamura S, Ueki T, Yao T, Ueyama T, Tsuneyoshi M (1994) Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. Cancer 73:2239–2249CrossRef

25.

Lim H, Park YS, Lee JH, Son DH, Ahn JY, Choi KS, Kim DH, Choi KD, Song HJ, Lee GH, Jung HY, Kim JH, Yook JH, Kim BS (2015) Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus. Clin Gastroenterol Hepatol 13:1738–1744.e2. https://doi.org/10.1016/j.cgh.2015.04.015 CrossRefPubMed

26.

Hissong E, Ramrattan G, Zhang P, Zhou XK, Young G, Klimstra DS, Shia J, Fernandes H, Yantiss RK (2018) Gastric carcinomas with lymphoid stroma: an evaluation of the histopathologic and molecular features. Am J Surg Pathol 42:453–462. https://doi.org/10.1097/PAS.0000000000001018 CrossRefPubMed

27.

Gullo I, Oliveira P, Athelogou M, Goncalves G, Pinto ML, Carvalho J, Valente A, Pinheiro H, Andrade S, Almeida GM, Huss R, Das K, Tan P, Machado JC, Oliveira C, Carneiro F (2019) New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer 22:77–90. https://doi.org/10.1007/s10120-018-0836-8 CrossRefPubMed

28.

Gullo I, Carvalho J, Martins D, Lemos D, Monteiro AR, Ferreira M, Das K, Tan P, Oliveira C, Carneiro F, Oliveira P (2018) The transcriptomic landscape of gastric cancer: insights into Epstein-Barr virus infected and microsatellite unstable tumors. Int J Mol Sci:19, E2079. https://doi.org/10.3390/ijms19072079 CrossRef

29.

Shinozaki-Ushiku A, Kunita A, Fukayama M (2015) Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol 46:1421–1434. https://doi.org/10.3892/ijo.2015.2856 CrossRefPubMed

30.

Uozaki H, Fukayama M (2008) Epstein-Barr virus associated gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1:198–216PubMedPubMedCentral

31.

Kenney SC, Mertz JE (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26:60–68. https://doi.org/10.1016/j.semcancer.2014.01.002 CrossRefPubMed

32.

Kaizaki Y, Sakurai S, Chong JM, Fukayama M (1999) Atrophic gastritis, Epstein-Barr virus infection, and Epstein-Barr virus-associated gastric carcinoma. Gastric Cancer 2:101–108CrossRef

33.

Hirano A, Yanai H, Shimizu N, Okamoto T, Matsubara Y, Yamamoto K, Okita K (2003) Evaluation of Epstein-Barr virus DNA load in gastric mucosa with chronic atrophic gastritis using a real-time quantitative PCR assay. Int J Gastrointest Cancer 34:87–94CrossRef

34.

Imai S, Nishikawa J, Takada K (1998) Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72:4371–4378CrossRef

35.

Nakayama A, Abe H, Kunita A, Saito R, Kanda T, Yamashita H, Seto Y, Ishikawa S, Fukayama M Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. PLoS One 14:e0211358. https://doi.org/10.1371/journal.pone.0211358 CrossRef

36.

Kanda T, Yajima M, Ikuta K (2019) Epstein-Barr virus strain variation and cancer. Cancer Sci 110:1132–1139. https://doi.org/10.1111/cas.13954 CrossRefPubMedPubMedCentral

37.

Corvalan AH, Ruedlinger J, de Mayo T, Polakovicova I, Gonzalez-Hormazabal P, Aguayo F (2019) The phylogeographic diversity of EBV and admixed ancestry in the Americas: another model of disrupted human-pathogen co-evolution. Cancers (Basel) 11:E217. https://doi.org/10.3390/cancers11020217 CrossRef

38.

Kaneda A, Matsusaka K, Aburatani H, Fukayama M (2012) Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 72:3445–3450. https://doi.org/10.1158/0008-5472.CAN-11-3919 CrossRefPubMed

39.

Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, Uozaki H, Seto Y, Takada K, Aburatani H, Fukayama M (2011) Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 71:7187–7197. https://doi.org/10.1158/0008-5472.CAN-11-1349 CrossRefPubMed

40.

Matsusaka K, Funata S, Fukuyo M, Seto Y, Aburatani H, Fukayama M, Kaneda A (2017) Epstein-Barr virus infection induces genome-wide de novo DNA methylation in non-neoplastic gastric epithelial cells. J Pathol 242:391–399. https://doi.org/10.1002/path.4909 CrossRefPubMed

41.

Goldenring JR, Nam KT (2010) Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci 96:117–131. https://doi.org/10.1016/B978-0-12-381280-3.00005-1 CrossRefPubMedPubMedCentral

42.

Port RJ, Pinheiro-Maia S, Hu C, Arrand JR, Wei W, Young LS, Dawson CW (2013) Epstein-Barr virus induction of the hedgehog signaling pathway imposes a stem cell phenotype on human epithelial cells. J Pathol 231:367–377. https://doi.org/10.1002/path.4245 CrossRefPubMed

43.

Shimizu T, Marusawa H, Matsumoto Y, Inuzuka T, Ikeda A, Fujii Y, Minamiguchi S, Miyamoto S, Kou T, Sakai Y, Crabtree JE, Chiba T (2014) Accumulation of somatic mutations in TP53 in gastric epithelium with helicobacter pylori infection. Gastroenterology 147:407–417.e3. https://doi.org/10.1053/j.gastro.2014.04.036 CrossRefPubMed

44.

Abe H, Kaneda A, Fukayama M (2015) Epstein-Barr virus associated gastric carcinoma: use of host cell machineries and somatic gene mutations. Pathobiology 82:212–223. https://doi.org/10.1159/000434683 CrossRefPubMed

45.

Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, Morikawa T, Nakaya T, Sakatani T, Takada K, Fukayama M (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69:2766–2774. https://doi.org/10.1158/0008-5472.CAN-08-3070 CrossRefPubMed

46.

Namba-Fukuyo H, Funata S, Matsusaka K, Fukuyo M, Rahmutulla B, Mano Y, Fukayama M, Aburatani H, Kaneda A (2016) TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. Oncotarget 7:81512–81526. https://doi.org/10.18632/oncotarget.13130 CrossRefPubMedPubMedCentral

47.

Funata S, Matsusaka K, Yamanaka R, Yamamoto S, Okabe A, Fukuyo M, Aburatani H, Fukayama M, Kaneda A (2017) Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget 8:55265–55279. https://doi.org/10.18632/oncotarget.19423 CrossRefPubMedPubMedCentral

48.

Birdwell CE, Queen KJ, Kilgore PC, Rollyson P, Trutschl M, Cvek U, Scott RS (2014) Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes. J Virol 88:11442–11458. https://doi.org/10.1128/JVI.00972-14 CrossRefPubMedPubMedCentral

49.

Hatakeyama M (2014) Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 15:306–316. https://doi.org/10.1016/j.chom.2014.02.008 CrossRefPubMed

50.

Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, Matsusaka K, Funata S, Kunita A, Urabe M, Seto Y, Fukayama M, Kaneda A, Hatakeyama M (2016) Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein-Barr virus. Nat Microbiol 1:16026. https://doi.org/10.1038/nmicrobiol.2016.26 CrossRefPubMed

51.

Cardenas-Mondragon MG, Torres J, Flores-Luna L, Camorlinga-Ponce M, Carreon-Talavera R, Gomez-Delgado A, Kasamatsu E, Fuentes-Panana EM (2015) Case control study of Epstein Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease. Br J Cancer 112:1866–1873. https://doi.org/10.1038/bjc.2015.175 CrossRefPubMedPubMedCentral

52.

Chen YC, Sheng J, Trang P, Liu F (2018) Potential application of the CRISPR/Cas9 system against herpes virus infections. Viruses 10:E291. https://doi.org/10.3390/v10060291 CrossRefPubMed

53.

van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E (2006) Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol 30:59–65CrossRef

54.

Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, Novario R, Capella C (2006) Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch 448:344–353. https://doi.org/10.1007/s00428-005-0066-4 CrossRefPubMed

55.

Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS (2017) Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget 8:26356–26367. https://doi.org/10.18632/oncotarget.15465 CrossRefPubMedPubMedCentral

56.

Ichimura T, Abe H, Morikawa T, Yamashita H, Ishikawa S, Ushiku T, Seto Y, Fukayama M (2016) Low density of CD204-positive M2-type tumor-associated macrophages in Epstein-Barr virus-associated gastric cancer: a clinicopathologic study with digital image analysis. Hum Pathol 56:74–80. https://doi.org/10.1016/j.humpath.2016.06.002 CrossRefPubMed

57.

Abe H, Morikawa T, Saito R, Yamashita H, Seto Y, Fukayama M (2016) In Epstein-Barr virus-associated gastric carcinoma a high density of CD66b-positive tumor-associated neutrophils is associated with intestinal-type histology and low frequency of lymph node metastasis. Virchows Arch 468:539–548. https://doi.org/10.1007/s00428-016-1915-z CrossRefPubMed

58.

Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK (2013) Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 9:e1003341. https://doi.org/10.1371/journal.ppat.1003341 CrossRefPubMedPubMedCentral

59.

Lu S, Wang LJ, Lombardo K, Kwak Y, Kim WH, Resnick MB (2019) Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes. Appl Immunohistochem Mol Morphol. https://doi.org/10.1097/PAI.0000000000000761

60.

Zhang NN, Chen JN, Xiao L, Tang F, Zhang ZG, Zhang YW, Feng ZY, Jiang Y, Shao CK (2015) Accumulation mechanisms of CD4(+)CD25(+)FOXP3(+) regulatory T cells in EBV-associated gastric carcinoma. Sci Rep 5:18057. https://doi.org/10.1038/srep18057 CrossRefPubMedPubMedCentral

61.

Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, Rabkin CS, Bass AJ (2016) Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget 7:32925–32932. https://doi.org/10.18632/oncotarget.9076 CrossRefPubMedPubMedCentral

62.

Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM (2018) Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open 3:e000326. https://doi.org/10.1136/esmoopen-2018-000326 CrossRefPubMedPubMedCentral

63.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer 22:69–76. https://doi.org/10.1007/s10120-018-0843-9 CrossRef

64.

Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M (2017) Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol 30:427–443. https://doi.org/10.1038/modpathol.2016.202 CrossRefPubMed

65.

Taieb J, Moehler M, Boku N, Ajani JA, Yanez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ (2018) Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: current status and future perspectives. Cancer Treat Rev 66:104–113. https://doi.org/10.1016/j.ctrv.2018.04.004 CrossRefPubMed

66.

Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J, Lunceford J, Savage MJ, Juco J, Emancipator K (2019) Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143:330–337. https://doi.org/10.5858/arpa.2018-0043-OA CrossRefPubMed

67.

Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S (2018) Immune activation and benefit from avelumab in EBV-positive gastric cancer. J Natl Cancer Inst 110:316–320. https://doi.org/10.1093/jnci/djx213 CrossRefPubMed

68.

Abe H, Saito R, Ichimura T, Iwasaki A, Yamazawa S, Shinozaki-Ushiku A, Morikawa T, Ushiku T, Yamashita H, Seto Y, Fukayama M (2018) CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8(+)/Foxp3(+) T cells. Virchows Arch 472:643–651. https://doi.org/10.1007/s00428-018-2332-2 CrossRefPubMed

69.

Murata Y, Saito Y, Kotani T, Matozaki T (2018) CD47-signal regulatory protein signaling system and its application to cancer immunotherapy. Cancer Sci 109:2349–2357. https://doi.org/10.1111/cas.13663 CrossRefPubMedPubMedCentral

70.

Polakovicova I, Jerez S, Wichmann IA, Sandoval-Borquez A, Carrasco-Veliz N, Corvalan AH (2018) Role of microRNAs and exosomes in Helicobacter pylori and Epstein-Barr virus associated gastric cancers. Front Microbiol 9:636. https://doi.org/10.3389/fmicb.2018.00636 CrossRefPubMedPubMedCentral

71.

Marquitz AR, Mathur A, Edwards RH, Raab-Traub N (2015) Host gene expression is regulated by two types of noncoding RNAs transcribed from the Epstein-Barr virus BamHI a rightward transcript region. J Virol 89:11256–11268. https://doi.org/10.1128/JVI.01492-15 CrossRefPubMedPubMedCentral

72.

Toptan T, Abere B, Nalesnik MA, Swerdlow SH, Ranganathan S, Lee N, Shair KH, Moore PS, Chang Y (2018) Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A 115:E8737–E8745. https://doi.org/10.1073/pnas.1811728115 CrossRefPubMedPubMedCentral

73.

Ungerleider N, Concha M, Lin Z, Roberts C, Wang X, Cao S, Baddoo M, Moss WN, Yu Y, Seddon M, Lehman T, Tibbetts S, Renne R, Dong Y, Flemington EK (2018) The Epstein Barr virus circRNAome. PLoS Pathog 14:e1007206. https://doi.org/10.1371/journal.ppat.1007206 CrossRefPubMedPubMedCentral

74.

Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Kosuga T, Komatsu S, Shiozaki A, Okamoto K, Imoto I, Otsuji E (2017) Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. Oncotarget 8:28796–28804. https://doi.org/10.18632/oncotarget.15675 CrossRefPubMedPubMedCentral

75.

Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K, Suehiro Y, Yamasaki T, Sakaida I (2018) Clinical importance of Epstein-Barr virus-associated gastric cancer. Cancers (Basel) 10:E167. https://doi.org/10.3390/cancers10060167 CrossRef

Title: Thirty years of Epstein-Barr virus-associated gastric carcinoma
Authors: Masashi Fukayama
Hiroyuki Abe
Akiko Kunita
Aya Shinozaki-Ushiku
Keisuke Matsusaka
Tetsuo Ushiku
Atsushi Kaneda
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Epstein-Barr Virus
Gastritis
Gastric Cancer
Gastric Cancer
Published in: Virchows Archiv / Issue 3/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02724-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thirty years of Epstein-Barr virus-associated gastric carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

In this issue

Correction to: Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme

Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report

Renal cell tumors with an entrapped papillary component: a collision with predilection for oncocytic tumors

Histological and molecular features of solitary fibrous tumor of the extremities: clinical correlation

A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration